$$
K 1 1 0 7 0 1
$$

# 510(k) Summary

This summary of the 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1900 and CFR 807.92.

Date:

30 November 2011

# Submitter:

DNA Genotek Inc. 2 Beaverbrook Road, Ottawa, Ontario K2K 1L1 Canada

# Contact:

Chantal Hemens-Davis   
Vice President Operations, Quality & Regulatory Affairs   
(Official Correspondent)   
Tel: (613) 723-5757 Ext. 238, Fax: (613) 368-4628   
Email: chantal.hemens-davis@dnagenotek.com

Device Proprietary Names

Oragene®Dx Formats: OGD-500, OGD-575, OXD-525, OYD-500

Common names

Kit for collection of Human DNA, Saliva kit, Sample collection kit

Regulatory Classification

Regulation: 21CFR 862.1675   
Panel: Chemistry (75)   
Classification: Class I1   
Product Code: OYJ DNA Specimen Collection, Saliva

Predicate Device

Vacutainer® Brand PPT Plasma Preparation Tube (k972075)

# DEVICE DESCRIPTION

The OrageD fmi  produc  elablcollection abilizatin,ranotatin n on-e room temperature storage of human DNA from saliva. Oragene-Dx is a non-invasive alternative for colletighigh quality and quantity DA for use in molecular dianostic applications. Allormats onsist of a collection tube, stabilizing liquid and optional sponges for assisted collection. After saliva is cl the abizi qui isi wihempl aliv n e elivdrcty by it using provided sponges to transfer saliva into the device.

# DNA Stabilization, Transportation and Storage

Upon contacting saliv cells, the stabilizing liquid lyses cellular and nuclear membranes to release and stabilize nucleic acids (DNA). Samples can be immediately processed, transported or stored for future use. Oragene·Dx samples are stable at room temperature for up to 12 months. Device and sample integrity are preserved during typical ambient transport and storage conditions.

# Sample Processing and Testing

DNA extraction from Oragene-Dx can be performed using alcohol precipitation for the purpose of molecular diagnostic applications.

# Intended Use

Oragene-Dx is intended for use in the non-invasive collection of saliva samples. DNA from the saliva sampl isolate stabiliz,and suitable orusen FDA cleared molecular dagnosicapplicatins. Salivamay be colleced by spit iretly into th OrageD cntaierr may beranerr into he OrageneDx containerusing a sponge.Saliva samples collected using OrageneDx are stabilized and can be transported and/or stored long term at ambient conditions.

# Indications for Use

See "Intended Use", above.

# COMPARISON TO MATERIAL AND TECHNOLOGICAL FEATURES OF THE PREDICATE DEVICE

T folowing table utlies he siilaries and differences between Vacutainer® Brand  Pa Preparation Tube (predicate) and Oragene-Dx Collection devices.

Table 25 - Similarities between Predicate and Oragene·Dx   

<table><tr><td colspan="1" rowspan="1">Principle,Materials andTechnology</td><td colspan="1" rowspan="1">Vacutainer® Brand PPT PlasmaPreparation Tube</td><td colspan="1" rowspan="1">Oragene·Dx</td><td colspan="1" rowspan="1">Similar</td><td colspan="1" rowspan="1">Different</td></tr><tr><td colspan="1" rowspan="1">Description ofIntended Use</td><td colspan="1" rowspan="1">The Vacutainer® Brand PPTPlasma Preparation Tube withEDTA anticoagulant and a gelbarrier material are evacuatedblood collection tubes whichprovide a means of collecting,processing and transporting bloodin a closed plastic tube. When theTube is used together withVacutainer® Brand Needles andHolders, it is a closed system forthe collection of venous blood withthe same indications identifiedhere.Blood collected in a tubecontaining EDTA anticoagulant andgel barrier material is usedprimarily to provide undilutedplasma for use in moleculardiagnostic test methods includingbut not limited to PCR (PolymeraseChain Reaction) and bDNA(branched DNA). The specimenmay also be used for other testingthat requires and undiluted plasmasample as determined by thelaboratory.</td><td colspan="1" rowspan="1">Oragene-Dx is intended for use inthe non-invasive collection of salivasamples. DNA from the salivasample is isolated, stabilized, andsuitable for use in FDA clearedmolecular diagnostic applications.Saliva may be collected by spittingdirectly into the Oragene Dxcontainer or may be transferred intothe Oragene Dx container using asponge. Saliva samples collectedusing Oragene-Dx are stabilized andcan be transported and/or storedlong term at ambient conditions.</td><td colspan="2" rowspan="1">X</td></tr><tr><td colspan="1" rowspan="1">Analyte</td><td colspan="1" rowspan="1">Various (including DNA)</td><td colspan="1" rowspan="1">DNA</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Samplecollection</td><td colspan="1" rowspan="1">Biological samples collectedthrough venous puncture into asterile plastic evacuatedcollection tube</td><td colspan="1" rowspan="1">Non-invasive collection of biologicalsamples delivered into a non-sterileplastic collection tube</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">X</td></tr><tr><td colspan="1" rowspan="1">Formats</td><td colspan="1" rowspan="1">Multiple</td><td colspan="1" rowspan="1">Multiple</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Tube material</td><td colspan="1" rowspan="1">Plastic</td><td colspan="1" rowspan="1">Plastic</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Sample source</td><td colspan="1" rowspan="1">Venous blood</td><td colspan="1" rowspan="1">Human saliva</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">X</td></tr><tr><td colspan="1" rowspan="1">Additive</td><td colspan="1" rowspan="1">EDTA and gel barrier material</td><td colspan="1" rowspan="1">Nucleic acid stabilization solution</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">X</td></tr><tr><td colspan="1" rowspan="1">Principle,Materials andTechnology</td><td colspan="1" rowspan="1">Vacutainer® Brand PPT PlasmaPreparation Tube</td><td colspan="1" rowspan="1">Oragene-Dx</td><td colspan="1" rowspan="1">Similar</td><td colspan="1" rowspan="1">Different</td></tr><tr><td colspan="1" rowspan="1">Transport andStability</td><td colspan="1" rowspan="1">Store unfilled tubes at 4-25°C.Limited excursion temperatures upto 40°C, for a cumulative time notto exceed 10 days, are acceptable.Whole blood may be stored in theBD PPT™ Tube up to six (6) hoursprior to centrifugation.</td><td colspan="1" rowspan="1">Pre-collection Oragene-Dx kits can betransported at temperatures rangingfrom -20°C to 50°Post-collection Oragene-Dx samplescan be transported at temperaturesranging from -20°C to 50°Pre-collection Oragene-Dx kits can bestored at room temperature for upto 24 monthsPost-collection Oragene-Dx samplescan be stored at room temperaturefor up to 12 months (OGD-500, OGD-575, 0YD-500) and 3 months forOXD-525</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">X</td></tr><tr><td colspan="1" rowspan="1">Suitabilityfor use withmoleculardiagnosticapplications</td><td colspan="1" rowspan="1">Used for testing plasma inmolecular diagnostics.</td><td colspan="1" rowspan="1">Stabilized DNA can be used inmolecular diagnostic testing.</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1"></td></tr></table>

# Substantial Equivalence Discussion

The similarities in intended use, materials, technological characteristics show that Oragene-Dx is substantially equivalent to Vacutainer® Brand PPT Plasma Preparation Tube. The differences tabulated above do not affect the safety and performance of Oragene Dx. Oragene Dx performance has been validated using GenMark Diagnostics' FDA cleared eSensor® Warfarin Sensitivity Saliva Test.

# PERFORMANCE CHARACTERISTICS

# Performance Characteristics of Oragene-Dx by Format

The DNA concentration and total sample DNA yield was determined by fluorescence and the A260/A280 ratio was determined by UV absorbance. These parameters were evaluated across allformats (OGD-500, OGD-575, OXD-525 and OYD-500). Data from a total of 450 samples from 245 unique donors is used in support of the performance characteristics for OGD-500. A subset of 45 donors is used in support of the performance characteristics for OXD-525 and OYD-500. A subset of 43 donors is used in support of the performance characteristics for OGD-575. All samples were extracted using an alcohol precipitation method. Downstream performance was demonstrated on the eSensor® Warfarin Sensitivity Saliva Test.

# Table 26 - Summary of DNA Yield Concentration and A260/A280 Ratio Results for Oragene-Dx Performance Characteristics

<table><tr><td rowspan=1 colspan=2>Y</td><td rowspan=1 colspan=1>OGD-500</td><td rowspan=1 colspan=1>OGD-575</td><td rowspan=1 colspan=1>OXD-525</td><td rowspan=1 colspan=1>OYD-500</td></tr><tr><td rowspan=1 colspan=2>Samples Tested</td><td rowspan=1 colspan=1>450</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>45</td></tr><tr><td rowspan=3 colspan=1>Yield (μg)</td><td rowspan=1 colspan=1>Mean ± SD</td><td rowspan=1 colspan=1>58.52 ± 47.02</td><td rowspan=1 colspan=1>13.50 ± 8.84</td><td rowspan=1 colspan=1>50.10 ± 42.38</td><td rowspan=1 colspan=1>56.05 ± 46.84</td></tr><tr><td rowspan=1 colspan=1>Median</td><td rowspan=1 colspan=1>48.44</td><td rowspan=1 colspan=1>10.96</td><td rowspan=1 colspan=1>33.35</td><td rowspan=1 colspan=1>37.28</td></tr><tr><td rowspan=1 colspan=1>95% of samples</td><td rowspan=1 colspan=1>≥ 13.1</td><td rowspan=1 colspan=1>≥3.8</td><td rowspan=1 colspan=1>≥ 14.8</td><td rowspan=1 colspan=1>≥ 13.0</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=3 colspan=1>Concentration (ng/μt)</td><td rowspan=1 colspan=1>Mean± SD</td><td rowspan=1 colspan=1>68.11 ± 55.27</td><td rowspan=1 colspan=1>41.12 ± 24.59</td><td rowspan=1 colspan=1>88.89 ± 74.51</td><td rowspan=1 colspan=1>65.38 ±55.94</td></tr><tr><td rowspan=1 colspan=1>Median</td><td rowspan=1 colspan=1>55.27</td><td rowspan=1 colspan=1>33.20</td><td rowspan=1 colspan=1>60.22</td><td rowspan=1 colspan=1>42.11</td></tr><tr><td rowspan=1 colspan=1>95% of samples</td><td rowspan=1 colspan=1>≥ 16.0</td><td rowspan=1 colspan=1>211.2</td><td rowspan=1 colspan=1>227.6</td><td rowspan=1 colspan=1>≥ 14.8</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=3 colspan=1>A260/A280 ratio</td><td rowspan=1 colspan=1>Mean ± SD</td><td rowspan=1 colspan=1>1.7 ± 0.1</td><td rowspan=1 colspan=1>1.7 ± 0.1</td><td rowspan=1 colspan=1>1.7 ± 0.1</td><td rowspan=1 colspan=1>1.7 ± 0.1</td></tr><tr><td rowspan=1 colspan=1>Median</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>1.7</td></tr><tr><td rowspan=1 colspan=1>98% of samples</td><td rowspan=1 colspan=1>1.5-2.0</td><td rowspan=1 colspan=1>1.5-1.9</td><td rowspan=1 colspan=1>1.5-1.9</td><td rowspan=1 colspan=1>1.5-1.9</td></tr></table>

Table 7  Summary  eSensor® Warfarin Sensitivity Saliva Test Results or OrageneDx Format Comparison   

<table><tr><td rowspan=1 colspan=1>Format</td><td rowspan=1 colspan=1>SNP</td><td rowspan=1 colspan=1>Samplestested</td><td rowspan=1 colspan=1>Correctcalls</td><td rowspan=1 colspan=1>Incorrectcalls</td><td rowspan=1 colspan=1>No-calls</td><td rowspan=1 colspan=1>% Correctcalls</td></tr><tr><td rowspan=3 colspan=1>OGD-500</td><td rowspan=1 colspan=1>2C9*2</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>2C9*3</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>VKORC1</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=3 colspan=1>OGD-575</td><td rowspan=1 colspan=1>2C9*2</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3†</td><td rowspan=1 colspan=1>93.0%</td></tr><tr><td rowspan=1 colspan=1>2C9*3</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3}$</td><td rowspan=1 colspan=1>93.0%</td></tr><tr><td rowspan=1 colspan=1>VKORC1</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>93.0%</td></tr><tr><td rowspan=3 colspan=1>OXD-525</td><td rowspan=1 colspan=1>2C9*2</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>2C9*3</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>VKORC1</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=3 colspan=1>OYD-500</td><td rowspan=1 colspan=1>2C9*2</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>2C9*3</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>VKORC1</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=7>After re-test</td></tr><tr><td rowspan=3 colspan=1>OGD-575</td><td rowspan=1 colspan=1>2C9*2</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>2C9*3</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>VKORC1</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr></table>

t First-pass no-call results were due to eSensor control failures.

# SAMPLE VOLUME TOLERANCE

A total of 240 samples were collected using OGD-500 with modified "fill to" lines (the volume of stabilizing liquid was kept constant at $2 m l$ in each of the devices) in order to simulate both under and over spitting. Collected sample volumes ranged from as low as $0 . 5 8 m L$ of saliva to as much as $3 . 6 4 m l$ EPY of saliva with a median collection volume of $2 m L$ .

As expcted the DNA yield was dependent n collectedvolume and neither he A260/A280 rato nr performance was affected by underorover spitting. Al samples contained sufficient DNA with suffcient quality to be used on the eSensor® Warfarin Sensitivity Saliva Test. All 4 samples gave a correct call after re-testing.

![](images/2d08068dc2a9acb87919fcdcd47d98b4f3440e60cc632132524e794c184f6dc1.jpg)  
Figure 1 - Collected Saliva Volume in Sample Volume Tolerance Study

# Table 28 - Summary of eSensor® Warfarin Sensitivity Saliva Test Results After Re-testing for Sample Volume Tolerance Study

<table><tr><td rowspan=1 colspan=1>Range of collected salivavolume (ml)</td><td rowspan=1 colspan=1>Samplestested</td><td rowspan=1 colspan=1>Correctcalls</td><td rowspan=1 colspan=1>Incorrect: calls</td><td rowspan=1 colspan=1>No-calls</td><td rowspan=1 colspan=1>% Correctcalls</td></tr><tr><td rowspan=1 colspan=1>0.58 - 3.64</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr></table>

One frst-pass o-l hi was olpon -tig.

# REPRODUCIBILITY

The OGD-500 device reproducibility study was conducted at three sites (two external and one internal). Three samples (collected using three lots of OGD-500) from each of ten donors, covering al possible gpes orreeals or he enor® Wa Senstiviy Saliv Te, we es in ply four different operators at the three sites. Each operator extracted DNA from each sample using the same alcohol precipitation method, followed by determination of DNA concentration and A260/A280 ratio for all samples by an independent operator at one of the sites. Four operators at three sites tested the extracted DNA samples on the eSensor® Warfarin Sensitivity Saliva Test. The following table summarizes the yield, DNA concentration and A260/A280 ratio results obtained by four operators at the three sites.

Table 29 - Summary of Device Reproducibility DNA Concentration, Yield and A260/A280 Results   

<table><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>Operator 1</td><td rowspan=1 colspan=1>Operator 2</td><td rowspan=1 colspan=1>Operator 3</td><td rowspan=1 colspan=1>Operator 4</td><td rowspan=1 colspan=1>Combined</td></tr><tr><td rowspan=1 colspan=2>Samples tested</td><td rowspan=1 colspan=1>87*</td><td rowspan=1 colspan=1>87*</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>354</td></tr><tr><td rowspan=3 colspan=1>Yield (μg)</td><td rowspan=1 colspan=1>Mean ± 50</td><td rowspan=1 colspan=1>74.89 ±68.00</td><td rowspan=1 colspan=1>76.68 ±61.76</td><td rowspan=1 colspan=1>69.59 ±57.24</td><td rowspan=1 colspan=1>77.40 ±68.36</td><td rowspan=1 colspan=1>74.62±63.79</td></tr><tr><td rowspan=1 colspan=1>Median</td><td rowspan=1 colspan=1>57.31</td><td rowspan=1 colspan=1>66.32</td><td rowspan=1 colspan=1>60.95</td><td rowspan=1 colspan=1>57.62</td><td rowspan=1 colspan=1>60.39</td></tr><tr><td rowspan=1 colspan=1>95% of samples</td><td rowspan=1 colspan=1>= 23.23</td><td rowspan=1 colspan=1>≥ 26.56</td><td rowspan=1 colspan=1>≥ 18.13</td><td rowspan=1 colspan=1>≥ 26.02</td><td rowspan=1 colspan=1>≥ 23.47</td></tr><tr><td rowspan=3 colspan=1>Concentration(ng/μL)</td><td rowspan=1 colspan=1>Mean ± SD</td><td rowspan=1 colspan=1>86.76 ±84.43</td><td rowspan=1 colspan=1>87.84±70.76</td><td rowspan=1 colspan=1>80.21 ±67.78</td><td rowspan=1 colspan=1>90.20 ±86.69</td><td rowspan=1 colspan=1>86.24 ±77.61</td></tr><tr><td rowspan=1 colspan=1>Median</td><td rowspan=1 colspan=1>63.83</td><td rowspan=1 colspan=1>74.43</td><td rowspan=1 colspan=1>68.82</td><td rowspan=1 colspan=1>66.20</td><td rowspan=1 colspan=1>68.58</td></tr><tr><td rowspan=1 colspan=1>95% of samples</td><td rowspan=1 colspan=1>≥ 25.87</td><td rowspan=1 colspan=1>≥ 29.58</td><td rowspan=1 colspan=1>≥ 20.42</td><td rowspan=1 colspan=1>≥ 28.98</td><td rowspan=1 colspan=1>≥ 26.74</td></tr><tr><td rowspan=3 colspan=1>A260/A280</td><td rowspan=1 colspan=1>Mean ± SD</td><td rowspan=1 colspan=1>1.9 ± 0.1</td><td rowspan=1 colspan=1>1.8 ± 0.1</td><td rowspan=1 colspan=1>1.9± 0.1</td><td rowspan=1 colspan=1>1.8 ± 0.1</td><td rowspan=1 colspan=1>1.9 ± 0.1</td></tr><tr><td rowspan=1 colspan=1>Median</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>1.9</td></tr><tr><td rowspan=1 colspan=1>95% of samples</td><td rowspan=1 colspan=1>1.6 - 2.3</td><td rowspan=1 colspan=1>1.6 - 2.1</td><td rowspan=1 colspan=1>1.7 - 2.0</td><td rowspan=1 colspan=1>1.5 - 2.0</td><td rowspan=1 colspan=1>1.6 - 2.2</td></tr></table>

O   ac

# Ta 0 ary Senr Warfa Sensvity Sal Te Result r Devi Repubil u Stratified by Site and Operator

First-pass   

<table><tr><td rowspan=2 colspan=1>Sire</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>POperator</td><td rowspan=1 colspan=1>SNP</td><td rowspan=1 colspan=1>Samplestested</td><td rowspan=1 colspan=1>Correctcalls</td><td rowspan=1 colspan=1>Incorrectcalls</td><td rowspan=1 colspan=1>No-calls</td><td rowspan=1 colspan=1>% Correctcalls</td></tr><tr><td rowspan=6 colspan=1>Site 1</td><td rowspan=3 colspan=1>Operator 1</td><td rowspan=1 colspan=1>2C9*2</td><td rowspan=1 colspan=1>87</td><td rowspan=1 colspan=1>86</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>98.9%</td></tr><tr><td rowspan=1 colspan=1>2C9*3</td><td rowspan=1 colspan=1>87</td><td rowspan=1 colspan=1>86</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>98.9%</td></tr><tr><td rowspan=1 colspan=1>VKOR</td><td rowspan=1 colspan=1>87</td><td rowspan=1 colspan=1>86</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>98.9%</td></tr><tr><td rowspan=3 colspan=1>Operator 2</td><td rowspan=1 colspan=1>2C9*2</td><td rowspan=1 colspan=1>87</td><td rowspan=1 colspan=1>86</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>98.9%</td></tr><tr><td rowspan=1 colspan=1>2C9*3</td><td rowspan=1 colspan=1>87</td><td rowspan=1 colspan=1>86</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>98.9%</td></tr><tr><td rowspan=1 colspan=1>VKOR</td><td rowspan=1 colspan=1>87</td><td rowspan=1 colspan=1>86</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>98.9%</td></tr><tr><td rowspan=3 colspan=1>Site 2</td><td rowspan=3 colspan=1>Operator 3</td><td rowspan=1 colspan=1>2C9*2</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>87</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>96.7%</td></tr><tr><td rowspan=1 colspan=1>2C9*3</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>97.8%</td></tr><tr><td rowspan=1 colspan=1>VKOR</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>87</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>96.7%</td></tr><tr><td rowspan=3 colspan=1>Site 3</td><td rowspan=3 colspan=1>Operator 4</td><td rowspan=1 colspan=1>2C9*2</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>47.8%</td></tr><tr><td rowspan=1 colspan=1>2C9*3</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>47.8%</td></tr><tr><td rowspan=1 colspan=1>VKOR</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>47.8%</td></tr></table>

# After re-testing and investigation

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Operator</td><td rowspan=1 colspan=1>SNP</td><td rowspan=1 colspan=1>Samplestested</td><td rowspan=1 colspan=1>Correctcalls</td><td rowspan=1 colspan=1>Incorrect&#x27;calls</td><td rowspan=1 colspan=1>No-calls</td><td rowspan=1 colspan=1>96 Correctcalls</td></tr><tr><td rowspan=6 colspan=1>Site 1</td><td rowspan=3 colspan=1>Operator 1</td><td rowspan=1 colspan=1>2C9*2</td><td rowspan=1 colspan=1>87</td><td rowspan=1 colspan=1>87</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%6</td></tr><tr><td rowspan=1 colspan=1>2C9*3</td><td rowspan=1 colspan=1>87</td><td rowspan=1 colspan=1>87</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>VKOR</td><td rowspan=1 colspan=1>87</td><td rowspan=1 colspan=1>87</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=3 colspan=1>Operator 2</td><td rowspan=1 colspan=1>2C9*2</td><td rowspan=1 colspan=1>87</td><td rowspan=1 colspan=1>87</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%6</td></tr><tr><td rowspan=1 colspan=1>2C9*3</td><td rowspan=1 colspan=1>87</td><td rowspan=1 colspan=1>87</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>VKOR</td><td rowspan=1 colspan=1>87</td><td rowspan=1 colspan=1>87</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>10096</td></tr><tr><td rowspan=3 colspan=1>Site 2</td><td rowspan=3 colspan=1>Operator 3</td><td rowspan=1 colspan=1>2C9*2</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%6</td></tr><tr><td rowspan=1 colspan=1>2C9*3</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%6</td></tr><tr><td rowspan=1 colspan=1>VKOR</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%6</td></tr><tr><td rowspan=3 colspan=1>Site 3</td><td rowspan=3 colspan=1>Operator 4</td><td rowspan=1 colspan=1>2C9*2</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>2C9*3</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>10096</td></tr><tr><td rowspan=1 colspan=1>VKOR</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>10096</td></tr></table>

t Incorrect call due to operator error resolved upon investigation. hrst-un no-a wer u to two runs (23 smples perun) invalidated due o DNA Contaminatn Monior (DCM) failures. The other hive first-pass no calls were low signal for the $2 0 9 ^ { \circ } 2$ allele (three), positive control failure (one) and contradictory score at the $2 5 9 ^ { \bullet } 3$ allele (one).

# STABILITY

Shelf-life conditions were evaluated by storing unused devices (OGD-500, OXD-525 and OYD-500) at room temperature, $6 ^ { \circ } C \pm 4 ^ { \circ } C$ or $- 2 0 ^ { \circ } C \pm 5 ^ { \circ } C$ for up to 24 months. OGD-575 was not tested as the chemistry is identical to the OGD-500 format. Devices were exposed to multiple freeze/thaw cycles of $- 2 0 ^ { \circ } \mathsf { C } \pm 5 ^ { \circ } \mathsf { C } / 5 0 ^ { \circ } \mathsf { C } \pm 5 ^ { \circ } \mathsf { C }$ In a separate study, devices were sent by standard mail to donors for collection and the donors mailed their samples directly to the processing laboratories. At all study time points a subset of devices were evaluated for physical and chemical properties to ensure the product specifications remained within acceptable tolerances. Another subset of devices was used to collect saliva from which DNA was extracted and analyzed for yield and A260/A280 ratio.

The data supports shelf-life claims of room temperature storage for up to 4 months. Additionally, the devices may be transported by standard mail at temperatures ranging from $- 2 0 ^ { \circ } C \pm 5 ^ { \circ } C$ to $5 0 ^ { \circ } C \pm 5 ^ { \circ } C$ .

Pot-collecinsample tability was evaluated by having 30 donrs each -collect fur saliv samples for each Oragene·Dx format (OGD-500, OXD-525 and OYD-500), for a study total of 360 samples. Samples were stored at room temperature, $6 ^ { \circ } C \pm 4 ^ { \circ } C$ or $- 2 0 ^ { \circ } C \pm 5 ^ { \circ } C$ for 12 months or at $5 0 ^ { \circ } C \pm 5 ^ { \circ } C$ for 3 months. At all study time-points, DNA was extracted and analyzed for yield and A260/A280 ratio. Samples stored at room temperature were analyzed for microbial content using a real-time PCR-based assay. A sub-population of samples (564 DNA samples across al time-points) were tested on the eSensor® Warfarin Sensitivity Saliva Test.

The data supports post-collection storage of OGD-500, OGD-575 and OYD-500 at $- 2 0 ^ { \circ } C$ to room temperature for up to 12 months and at $5 0 ^ { \circ } C \pm 5 ^ { \circ } C$ for 3 months. The data supports post-collection storage of OxD-525 at room temperature for up to 3 months. All formats stored at room temperature for 12 months exhibited no significant change in microbial content.

# INTERFERING SUBSTANCES

Both endogenous (amylase, hemoglobin, IgA, total protein) and exogenous (eating, drinking, chewing gum, mouthwash, smoking) potentially interfering substances were added separately to samples from donors with known genotypes. Addition of tested substances had no effect as demonstrated through teting on the eSensor® Warfarin Sensitivity Saliva Test. All samples gave a correct call on first-pass.

# CONCLUSION

The submitted information in this premarket notification is complete and supports the safety and effectiveness of the Oragene-Dx family of collection devices.

DNA Genotek, Inc. c/o Chantal Hemens-Davis 2 Beaverbrook Road Ottawa, Ontario K2K 1L1 Canada

Re: k110701 Trade Name: Oragene·Dx OGD-500, Oragene·Dx OGD-575, Oragene·Dx OXD-525, Oragene·Dx OYD-500 Regulation Number: 21 CFR $\ S 8 6 2 . 1 6 7 5$ Regulation Name: Blood specimen collection device Regulatory Class: Class II Product Codes: OYJ Dated: October 24, 2011 Received: October 25, 2011

Dear Ms. Hemens-Davis:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2 -

If you desire specific advice for your device on our labeling regulation (21 CFR Par 801), please contact the Office of In Virro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the rlatnti, "irni  c  t"    0.9F B (S's) Division of Postmarket Surveillance at (301) 796-5760.For questions regarding the reporting of averse events under the MDR egulatio (21 CFR P 803), pleas to   
http://www.da.gov/MedicalDevices/Safety/ReportaProblem/deaul.htmor the CDRH'sOffico Surveillance and Biometrics/Division of Postmarket Surveillance.

Yu maybta ohrgnaloation n youreonsibilis nderheAc o he Divisn mal Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041or (301796- 5680 or at its Internet address htp://www.fda.gov/MedicalDevices/ResourcesforYou/ndustry/defauit.htm.

Sincerely yours,

![](images/586c7c626ee597e9afb030887431e1454b9f29d2afcd65e82f3cc807c9afdc5b.jpg)

Courtney H. Lias, Ph.D.   
Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

# Indications for Use Form

510(k) Number (if known): k110701

Device Name: Oragene® Dx Collection Devices: OGD-500; OGD-575; OXD-525; OYD-500

Indications for Use:

Oragene-Dx is intended for use in the non-invasive collection of saliva samples. DNA from the saliva s  latabi tab FA cleorps. Saliva may be colect by spitti dret into theOrageD cntaer may beranerr ino e OrageneDx container using a sponge. Saliva samples collected using Oragene-Dx are stabilized and can be transported and/or stored long term at ambient conditions.

Prescription Use_X (21 CFR Part 801 Subpart D)

And/Or

Over the Counter Use (21 CFR Part 801 Subpart C)

![](images/2b9277bcac7ba3f9e208d905960e70577a4d70b106ff209f5593e6daa8635a55.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
510(k) K11070